Post Offer Free
Wuhan Yuancheng Gongchuang Technology Co,ltd
Wuhan Yuancheng Gongchuang Technology Co,ltd

China Glibenclamide USP/Cp/Ep/Jp/Bp CAS 10238-21-8 Glibenclamide manufacturer

2nd

Gold Index: 167643

You are here: home  > Pharmaceutical raw material  > Other pharmaceuticals  > Glibenclamide USP/Cp/Ep/Jp/Bp CAS 10238-21-8 Glibenclamide

Glibenclamide USP/Cp/Ep/Jp/Bp CAS 10238-21-8 Glibenclamide 

Price: 90.0 USD 
Payment Terms: T/T,WU,Money Gram 
Place of Origin: Hubei, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Means of Transport: Ocean,Land,Air
Packing: disguise package or as requ...
Brand Name: gongchuang
Purity: 99%
source: Glibenclamide source
supplier: Glibenclamide supplier
Usage: Glibenclamide Usage
purity: 99% min
Standard: USP/BP/USP
Production Capacity: 500kg//month
Delivery Date: 4-15days
CAS No.: 10238-21-8
Alias: Glibenclamide
usage: Glibenclamide usage
price: Glibenclamide price
effects: Glibenclamide
Appearance: powder

Pharmaceutical Raw Materials Glibenclamide CAS 10238-21-8;
Blood System Agents Glibenclamide;
Antidiabetic Raw Powder Glibenclamide CAS 10238-21-8

 Blood System Agents Glibenclamide with high Quality 
 

Product NameGlibenclamide
Synonymsglybenclamide; glyburide usp; Glibenclamide; Glyburide; HB-419; maninil; adiab;; 5;Abbenclamide;adiab
CAS No.10238-21-8
EINECS No.233-570-6
Molecular FormulaC23H28ClN3O5S
Molecular Weight494.01
Melting point168-173ºC
Appearancewhite crystalline powder
Applicationmedical use.Hypoglycemic drug, for the treatment of mild, non insulin dependent diabetes mellitus.
 


Glibenclamide, also known as glyburide, is an antidiabetic drug in a class of medications known as sulfonylureas, closely related to sulfonamide antibiotics.

Glibenclamide is an oral sulfonylurea hypoglycaemic agent indicated in the treatment of non-insulin-dependent diabetes in patients who fail to respond to dietary measures alone. Glibenclamide may be used in conjunction with metformin or insulin. Glibenclamide may be considered in the treatment of gestational diabetes where metformin is ineffective or not tolerated, and where treatment with insulin is declined.

Data on the use of glibenclamide in pregnancy consist of >9,500 exposures, although as glibenclamide is used in the management of gestational diabetes, first trimester exposure data are lacking and an increased risk of congenital malformation or spontaneous abortion cannot be excluded. 

Data regarding risk of large for gestational age or macrosomia in the infant, neonatal hypoglycaemia and admission to a neonatal intensive care unit with glibenclamide treatment of gestational diabetes when compared to insulin and/or metformin, are conflicting, possibly as a result of confounding from variation in maternal obesity and glycaemic control, both of which are known to significantly affect these outcomes. No increased risks were identified for intrauterine death or preterm delivery.

Exposure to glibenclamide at any stage of pregnancy would not usually be regarded as medical grounds for termination of pregnancy or any additional fetal monitoring. However, women with diabetes may require additional monitoring of fetal growth and amniotic fluid volume irrespective of medication. Other risk factors may be present in individual cases which may independently increase the risk of adverse pregnancy outcome. Clinicians are reminded of the importance of consideration of such factors when performing case-specific risk assessments.


Glibenclamide COA

ITEMSTANDARDRESULTS
AppearanceCrystalline powderConforms
Melting range129°C~132°C130.8°C-131°C
Loss on drying≤0.5%0.20 %
Specific rotation-58°~-62°(C=1,in CH3OH)-61.05°
Sulphated ash≤0.1%0.08 %
Heavy metals≤10ppmConforms
Chlorides≤0.02%Conforms
Sulfates≤0.02%Conforms
Fluorine14.7%~17.9%15.2%
Residual solventMethanol ≤0.2%
Isopropanol ≤0.2%
Ethyl acetate≤0.2%
Chloroform ≤0.2%
0.0%
0.0%
0.0%
0.0%
Related substances
(HPLC)
Single impurity ≤0.2%
Total impurities ≤0.5%
0.05%
0.08%
Assay≥99.5%99.92%
ConclusionAccordance with the reference


Function                                                  
Hypoglycaemic. Inhibit decomposition of glycogen and Gluconeogenesis, reduce glucoses production and output in liver;Besides, it can strengthen pancreass sensitivity to insulin and consume more sugar,reducing FPG and P2hPG. For the second-generation sulfonylurea drug, there is a strong role in lowering blood glucose, its hypoglycemic effect than D-860 Strong 100-fold. Fasting blood glucose after treatment compared with postprandial blood glucose significantly decreased, respectively, reduced by about 35%, and 21% or less.Easily absorbed from the gastrointestinal tract, plasma protein binding rate is high.Fall blood sugar function strong, Glyburide capsule: its role a toluene sulfonylurea urea butyl 100 times stronger. Oral 30 minutes later appeared for about 16 ~ role 24 hours. Easily absorbed from the gastrointestinal tract, plasma protein binding rate is high. T1/2 about 10 h. Almost all by hepatic metabolism, the main metabolites hypoglycemic activity is weak. About 50% of metabolites from urine discharge, and another 50% by bile into debris. 
Glyburide piece: this product is lowering blood sugar pills. 1. Stimulate pancreatic beta cells secrete insulin, a prerequisite, there is still a beta cell synthesis and secretion of insulin function; Through the increase insulin 
levels for the liver or portal vein direct action, inhibit liver glycogen decomposition and glycogen vision, liver function was born generation and output glucose reduced; 3. Also may increase the organization for pancreatic insulin sensitiity and sugar (mainly through the use of possible receptors, therefore, the role) function is reduced fasting blood sugar and blood glucose after a meal. 
 
Application                                             
Acarbose is an anti-diabetic drug used to treat type 2 diabetes mellitus and, in some countries, prediabetes. It is sold in Europe under the brand name Glucobay (Bayer AG), in North America as Precose 
(BayerPharmaceuticals), and in Canada as Prandase (Bayer AG). It is an inhibitor of alpha glucosidase, an enteric enzyme that releases glucose from larger carbohydrates.

Antineoplastic Powder:

Letrozol.

CAS:112809-51-5

Anastrozol.(Arimidex)

CAS:120511-73-1

L-Triiodothyronine(T3)

CAS:55-06-1

Trilostan.

CAS:13647-35-3

Formestan.

CAS:566-48-3

.(Aromasin)

CAS:107868-30-4



Estrogen Hormone/Estrogen-blocking Powder:


Tamoxifen Citrate(Nolvadex)

CAS:54965-24-1

Clomiphene Citrate(Clomid)

CAS:50-41-9

Progesterone

CAS: 57-83-0

Estradiol

CAS: 50-28-2

Estradiol valerate

CAS: 979-32-8

Diethylstilbestrol

CAS: 56-53-1

Hexestrol

CAS:84-16-2



Surface Anesthesia Powder:


Benzocaine

CAS:94-09-7

Tetracaine Hydrochloride

CAS:136-47-0

Procaine Hydrochloride

CAS:51-05-8

Lidocaine Hydrochloride

CAS:6108-05-0

Lidocaine Base

CAS:137-58-6

Aarticaine Hydrochloride

CAS:23964-57-0

Dyclonine Hydrochloride

CAS:536-43-6

Levobupivacaine Hydrochloride

CAS:27262-48-2

Propitocaine hydrochloride

CAS:1786-81-8

Ropivacaine Mesylate

CAS:854056-07-8

Tetracaine Hydrochloride

CAS:136-47-0


 


Ms. Gina
skype Ms. Gina
Manager
Tel: 86-27-88211875
Mobile: 188 7222 0799
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info

Wuhan Yuancheng Gongchuang Technology Co,ltd [China (Mainland)]


Business Type:Manufacturer, Trading Company
City: Wuhan
Province/State: Hubei
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin Follow us on Twitter

Gina:   skype
Service:   skype

You May Like: